2023年12月9日 · The randomised, phase 3 KEYNOTE-811 study (NCT03615326) evaluated the efficacy and safety of the addition of either pembrolizumab or placebo to trastuzumab plus fluoropyrimidine and platinum-based chemotherapy (fluorouracil plus cisplatin or capecitabine plus oxaliplatin) in patients with untreated HER2-positive metastatic gastric or gastro ...

Here we describe results of the protocol-specified first interim analysis of the randomized, double-blind, placebo-controlled phase III KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for unresectable or metastatic, HER2-positive gastric or gastro-oesophageal junction adenocarcinoma 22 ( https://clinicaltrials.gov ...

2024年5月1日 · KEYNOTE-811 is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, NCT03615326) evaluating KEYTRUDA in combination with trastuzumab and chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma.

2023年12月9日 · The first interim analysis of the randomised, phase 3 KEYNOTE-811 study showed a superior objective response with pembrolizumab compared with placebo when added to trastuzumab plus fluoropyrimidine and platinum-based chemotherapy.

2023年12月9日 · The first interim analysis of the randomised, phase 3 KEYNOTE-811 study showed a superior objective response with pembrolizumab compared with placebo when added to trastuzumab plus fluoropyrimidine and platinum-based chemotherapy.

2024年10月23日 · In a phase III, international, double-blind, randomised, placebo-controlled KEYNOTE-811 study, adding pembrolizumab to trastuzumab and chemotherapy provided a significant improvement in overall survival (OS) as compared with trastuzumab and chemotherapy alone as first-line therapy for patients with unresectable or metastatic HER2-positive ...

2024年9月13日 · The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.

2021年12月15日 · KEYNOTE-811 is a global randomized, double-blind, placebo-controlled, phase III study designed to assess the efficacy and safety of adding pembrolizumab to standard-of-care therapy with ...

2019年5月26日 · KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study. Authors: Yelena Yuriy Janjigian, Yung-Jue Bang, Charles S. Fuchs, Shukui Qin, Taroh Satoh, Kohei Shitara, Josep Tabernero, …

2022年1月11日 · Interim data for the phase III KEYNOTE-811 trial (NCT03615326) assessing a combination of the anti-PD1 antibody pembrolizumab, the anti-HER2 antibody trastuzumab, and chemotherapy for patients...